NCT00638807

Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 388 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

To compare the efficacy and safety of celecoxib versus placebo for the treatment of knee osteoarthritis (OA) in patients who were unresponsive to prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen

Conditions

• Osteoarthritis, Knee

Interventions

Type	Name	Description
DRUG	Celecoxib	200 mg oral capsule once daily with morning meal for 6 weeks
OTHER	Placebo	Matched oral placebo for 6 weeks

Timeline

• Start date: 2003-12-01
• Completion: 2004-07-01
• First posted: 2008-03-19
• Last updated: 2021-02-02

Locations

33 sites across 1 country: United States